LTX-401 dihydrochloride
目录号 : GC61012
LTX-401是一种可靶向作用高尔基体(Golgiapparatus)的溶瘤氨基酸衍生物。
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
LTX-401, an oncolytic amino acid derivative, targets the Golgi apparatus.
LTX-401, an oncolytic amino acid derivative, targets the Golgi apparatus[2]. LTX-401 effectively reduces the viability of several tumor cell lines in vitro, with a similar degree of cytotoxicity against non-malignant cell lines such as HUV-EC-C endothelial cells, HaCat keratinocytes and MRC-5 fibroblasts. LTX-401 displays the highest cytotoxic activity against the human malignant melanoma cell line MDA-MB-435S (13.5 μM), and is least active against the human hepatocellular carcinoma cell line HEPG2 (35.4 μM). For the remaining cell lines, LTX-401 exhibits similar IC50 values, varying slightly within the range of 19-32 μM. No in vitro hemolytic activity against RBCs is observed using the same concentrations required for the induction of cell death in cancer cell lines. A 50% hemolysis is observed using higher concentrations of LTX-401 (400 μg/mL=1087 μM)[1].
The majority (9/11) of the animals demonstrate a complete and lasting tumor regression after intratumoral treatment with LTX-401. Samples are collected from selected animals in the treatment group and control group on days 2 and 7 post-treatment with a single i.t injection. The immunolabelling of tumor tissue with anti-CD3 antibody reveals that a majority of the infiltrating cells are CD3+ T cells, whereas tumors injected with vehicle only exhibit tumors with a viable tumor tissue, with minimal necrosis and few lymphocytes[1].
[1]. Liv-Marie Eike, et al. The Cytolytic Amphipathic β(2,2)-Amino Acid LTX-401 Induces DAMP Release in Melanoma Cells and Causes Complete Regression of B16 Melanoma. PLoS One. 2016; 11(2): e0148980. [2]. Heng Zhou, et al. The oncolytic compound LTX-401 targets the Golgi apparatus. Cell Death Differ. 2018 Jan; 25(1): 227-228.
| Cas No. | SDF | ||
| Canonical SMILES | [NH3+]CC(CCCC1=CC=CC=C1)(C(NCC[NH3+])=O)CCCC2=CC=CC=C2.[Cl-].[Cl-] | ||
| 分子式 | C23H35Cl2N3O | 分子量 | 440.45 |
| 溶解度 | DMSO: 100 mg/mL (227.04 mM) | 储存条件 | 4°C, away from moisture |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.2704 mL | 11.352 mL | 22.7041 mL |
| 5 mM | 0.4541 mL | 2.2704 mL | 4.5408 mL |
| 10 mM | 0.227 mL | 1.1352 mL | 2.2704 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。